ClinicalTrials.gg
SuspendedNCT02904304Updated Jul 8, 2019

Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu

A Phase 3 interventional study of Desloratadine+Phenylephrine+Ibuprofen and Placebo in Cold, sponsored by Ache Laboratorios Farmaceuticos S.A.. Suspended at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

Why this study was suspended
the viability of the study is being analyzed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Common Cold with a site in Brazil — 1 open to participants now, 1 under way, 1 of them phase 3. Common Cold · Brazil.

Planned enrollment
7th of 12
150 · median 183
Started
2020
the only one that year
Phase 3
11 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
3 of 12
Ache Laboratorios Farmaceuticos S.A.

Among the 12 studies in Common Cold with a site in Brazil, this one is the 7th largest by planned enrollment, is the only one that started in 2020, is one of 11 in phase 3, and was the 10th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

1 of the 12 studies in Common Cold with a site in Brazil is open now. Recruiting first, the newest first:

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Common Cold with a site in Brazil, or all of them as a file.
02

Study summary

National clinical trial, phase III, multicenter, randomized, prospective, double-blind, parallel, placebo-controlled, which one hundred and fifty (150) subjects of both sexes aged equal or more than 18 years will be randomly allocated to one the drug group or placebo group.

Read the detailed description

The investigational product is a combination of desloratadine, phenylephrine hydrochloride and ibuprofen.

The desloratadine is a antihistamine and selectively block the activity of histamine receptor-1 (H1) resulting in a non sedative and prolong antiallergic effect.

The phenylephrine is a potent stimulator of the postsynaptic α receptor with minimal effect on β receptors in the heart.

The ibuprofen's mechanism is not fully known. It is a non selective inhibitor of cyclooxygenase, an enzyme that is involved in prostaglandin synthesis by the route from arachidonic acid. It is believed that the pharmacological effects are due to inhibition of cyclooxygenase-2 (COX-2), which reduces prostaglandin synthesis involved in the mediation of inflammation, pain, fever and swelling.

03

Conditions studied

  • Cold

Keywords

  • Flu
  • Treatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age older or equal to 18 and younger than 66 years;
  • Subjects diagnosed with common cold / flu syndrome defined by clinical evaluation and the presence of two or more of the following symptoms: sneezing, rhinorrhea, nasal obstruction, headache, throat discomfort, sore throat, dysphonia, myalgia, cough and fever classified as moderate or intense in four intensity scale (04) items (0 = absent, 01 = light, 02 = moderate, 03 = severe);
  • Beginning of the symptoms of common cold / flu-like syndrome in a minimum period of 24 hours and a maximum of 72 hours prior to V0;
  • Ability to understand and consent to participate in this clinical research, expressed by signing the Form (ICF);

Exclusion criteria

Exclusion Criteria:

  • Any laboratorial finding (clinical evaluation / physical evaluation / vital signs / changes) that the Investigator consider a risk to subject of the study;
  • to the drug components used during the study;
  • Women in pregnancy or nursing period;
  • Women in reproductive age who do not agree to use acceptable [oral contraceptives, injectable contraceptives, intrauterine device (IUD), hormonal implants, barrier methods, hormonal patch and tubal ligation]; other than surgically sterile (bilateral oophorectomy or hysterectomy), for at least one (01) years or sexual abstinence;
  • Subjects that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
  • Alcohol abuse that, according to the investigator, may interfere with the pharmacological adherence to the clinical protocol;
  • Any medical conditions which may interfere with efficacy and / or safety of the treatment with the product, such as but not limited to disorders described below:
  • Untreated or uncontrolled Hyperthyroidism
  • Uncontrolled epilepsy
  • diagnosis of glaucoma
  • Moderate or severe persistent asthma (untreated or uncontrolled)
  • NSAID-induced asthma diagnosed
  • Systemic hypertension (SH) stage III uncontrolled
  • Moderate and severe congestive heart failure
  • Acute myocardial infarction
  • unstable angina
  • Uncontrolled cardiac arrhythmia
  • Liver failure with clinical consequences
  • Renal failure with clinical consequences
  • Diagnosed positive
  • uncontrolled Diabetes type 1 or type 2
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Desloratadine+Phenylephrine+Ibuprofen

    It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg. Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants.

    Drug: Desloratadine+Phenylephrine+Ibuprofen

  • Placebo comparator
    Placebo

    It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study. The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug.

    Drug: Placebo

Interventions

  • DrugDesloratadine+Phenylephrine+Ibuprofen

    Drug pages: Desloratadine · Phenylephrine · Ibuprofen

    01 tablet, orally, every 12 hours.

    Also known as: Desloratadine+Phenylephrine hydrochloride+Ibuprofen

  • DrugPlacebo

    01 tablet, orally, every 12 hours.

06

What researchers measure

Primary outcomes

  1. Evaluation of the superiority of Desloratadine + Phenylephrine + Ibuprofen over placebo

    To evaluate the association of the superiority fixed dose of desloratadine 2.5mg, 20mg phenylephrine hydrochloride and ibuprofen 400 mg compared to placebo in the treatment of symptoms related to the common cold / flu syndrome by varying the intensity total score of symptoms, three (03 ) hours after the first dose of investigational product.

    Time frame: 03 hours after the first dose

Secondary outcomes

  1. Evaluation of the symptoms related to the common cold / flu syndrome.

    Absolute variation in total score intensity of symptoms related to the common cold / flu-like symptoms 02 days after the start of treatment compared to baseline.

    Time frame: 02 days after initiation of treatment, compared to baseline.

  2. Satisfaction of the quality of sleep

    Distribution of subjects in each treatment group as their perception to the sleep quality, assessed at baseline by answering the following statement: " Last night, with this cold, I did not sleep as well as I usually sleep "based on a scale of 0 to 4 points (0 = strongly disagree, 1 = disagree, 2 = neither agree nor disagree, 3 = agree and 4 = I totally agree).

    Time frame: On the first day and on the second day after the start of treatment.

  3. The need for use of the rescue medication measured through the subject's diary.

    Proportion of subject in each treatment group who used at least once the rescue medication (Tylenol®) in the first (Day 01) and on the second day (day 02) after treatment, measured through the subject's diary.

    Time frame: On the first day and on the second day after the start of treatment.

  4. The need for use of the rescue medication according to accounting of rescue medication returned.

    Proportion of subject in each treatment group who used at least once the rescue medication (Tylenol®) in the first (Day 01) and on the second day (day 02) after treatment, accounting of rescue medication (Tylenol®) returned.

    Time frame: On the first day and on the second day after the start of treatment.

07

Study locations

1 site
  • Allergisa Pesquisa Dermato Cosmética Ltda.
    Campinas, São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2020; primary completion for Jul 2021, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2016
First posted
Sep 16, 2016
StartEst.
Dec 2020
Primary completionEst.
Jul 2021
CompletionEst.
Sep 2021
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02904304
Responsible party
Sponsor
First posted
Sep 16, 2016
Start date
Dec 2020 (estimated)
Primary completion
Jul 2021 (estimated)
Completion
Sep 2021 (estimated)
Last update
Jul 8, 2019

Study contacts

Mauro Crippa Jr.
principal investigator · Allergisa Pesquisa Dermato-Cosmética Ltda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desloratadine · Phenylephrine · Ibuprofen

Start the discussion